# IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

> **NCT05991518** · PHASE1,PHASE2 · UNKNOWN · sponsor: **SUNHO（China）BioPharmaceutical CO., Ltd.** · enrollment: 136 (estimated)

## Conditions studied

- HER2 Gene Mutation

## Interventions

- **COMBINATION_PRODUCT:** Injection of IAH0968+Gemcitabine+Cisplatin
- **COMBINATION_PRODUCT:** Gemcitabine+Cisplatin

## Key facts

- **NCT ID:** NCT05991518
- **Lead sponsor:** SUNHO（China）BioPharmaceutical CO., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-25
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05991518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05991518, "IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05991518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*